ELITE II和Val-HeFT是不同的试验：它们共同告诉了我们什么？
ELITE II and Val-HeFT are different trials: together what do they tell us?
作者信息
Dickstein Kenneth
机构信息
University of Bergen, Cardiology Department, Central Hospital in Rogaland, Stavanger, 4011, Norway.
出版信息
Curr Control Trials Cardiovasc Med. 2001;2(5):240-243. doi: 10.1186/cvm-2-5-240.
The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective angiotensin II receptor antagonist on morbidity and mortality in patients with symptomatic heart failure. The trials differed, however, in terms of their primary hypothesis, study design, and treatment regimens, and this must be taken into consideration when comparing and interpreting the data from these studies. The data are in many ways complementary, and add to our understanding of the optimal treatment of symptomatic heart failure. Additional studies are needed, however, to fully define the role of angiotensin II receptor antagonists in the management of this very heterogeneous group of patients.
氯沙坦心力衰竭生存研究（ELITE II）和缬沙坦心力衰竭试验（Val-HeFT）均评估了选择性血管紧张素II受体拮抗剂对有症状心力衰竭患者发病率和死亡率的疗效及耐受性。然而，这两项试验在主要假设、研究设计和治疗方案方面存在差异，在比较和解读这些研究的数据时必须考虑到这一点。这些数据在很多方面是互补的，有助于我们加深对有症状心力衰竭最佳治疗方法的理解。不过，还需要更多研究来全面明确血管紧张素II受体拮抗剂在这类异质性很强的患者群体管理中的作用。
Zotero 插件